Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AELIS.PA
- Price
- 1.18
- Stock movement down
- -0.03 (-2.11%)
- Company name
- Aelis Farma SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 18.93M
- Ent value
- 17.60M
- Price/Sales
- 2.22
- Price/Book
- 3.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 8.18
- PEG
- -
- EPS growth
- 16.44%
- 1 year return (CAGR)
- -33.81%
- 3 year return (CAGR)
- -53.93%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-13
DIVIDENDS
AELIS.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.22 |
| Price to Book | 3.10 |
| EV to Sales | 2.07 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 13.62M |
| EPS (TTM) | -0.99 |
| FCF per share (TTM) | -1.15 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.52M |
| Gross profit (TTM) | 8.52M |
| Operating income (TTM) | -13.71M |
| Net income (TTM) | -13.57M |
| EPS (TTM) | -0.99 |
| EPS (1y forward) | 0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -160.96% |
| Profit margin (TTM) | -159.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 10.79M |
| Net receivables | 12.00K |
| Total current assets | 14.12M |
| Goodwill | 0.00 |
| Intangible assets | 190.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 15.58M |
| Accounts payable | 1.03M |
| Short/Current long term debt | 6.89M |
| Total current liabilities | 4.43M |
| Total liabilities | 9.46M |
| Shareholder's equity | 6.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -19.62M |
| Capital expenditures (TTM) | 278.50K |
| Free cash flow (TTM) | -15.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -221.96% |
| Return on Assets | -87.11% |
| Return on Invested Capital | -166.22% |
| Cash Return on Invested Capital | -192.64% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.42 |
| Daily high | 1.45 |
| Daily low | 1.36 |
| Daily Volume | 50K |
| All-time high | 14.28 |
| 1y analyst estimate | 11.00 |
| Beta | 0.66 |
| EPS (TTM) | -0.99 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 30 Mar 2026 |
Downside potential
Loading...
Downside potential data
| AELIS.PA | S&P500 | |
| Current price drop from All-time high | -91.77% | -0.89% |
| Highest price drop | -95.00% | -56.47% |
| Date of highest drop | 21 Jul 2025 | 9 Mar 2009 |
| Avg drop from high | -38.02% | -10.86% |
| Avg time to new high | 64 days | 12 days |
| Max time to new high | 763 days | 1805 days |
COMPANY DETAILS
Marketcap
18.93M
Marketcap category
Small-cap
Description
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Employees
24
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The global cannabis use disorder market is rapidly expanding, driven by increased recognition of cannabis use as a public health issue and the ongoing development of investigational treatments, includ...
February 6, 2026
BORDEAUX, France, January 26, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of t...
January 26, 2026
As European markets start the year with optimism, the pan-European STOXX Europe 600 Index has risen by 2.27%, buoyed by positive economic signals and a favorable interest rate environment. In this con...
January 15, 2026
BORDEAUX, France, January 12, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of t...
January 12, 2026
As the pan-European STOXX Europe 600 Index edges closer to record highs amid optimism about future earnings and economic prospects, investors are keenly observing the high-growth tech sector, which re...
December 31, 2025
As European markets close out a holiday-shortened week, the pan-European STOXX Europe 600 Index edged slightly higher, buoyed by positive sentiment around future earnings and economic prospects. In th...
December 29, 2025
As European markets show signs of steady economic growth with the STOXX Europe 600 Index rising by 1.60%, looser monetary policies and stable interest rates across major economies like the UK and Euro...
December 23, 2025
BORDEAUX, France, December 02, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for bra...
December 2, 2025
The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% due to relief from the reopening of the U.S. federal government, although enthusiasm for artifici...
November 21, 2025
As the European market navigates a mixed landscape, with the pan-European STOXX Europe 600 Index recently dipping by 0.67% amid tempered expectations for further ECB rate cuts, investors are keenly ob...
November 3, 2025
Next page